Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. (Israel) is dated March 21, 2018. The document serves as a Notice of Annual General Meeting of Shareholders scheduled for May 2, 2018. The filing incorporates by reference the notice posted on the company's website and allows shareholders to review financial statements for the fiscal year ended December 31, 2017.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. It references the availability of financial statements for the fiscal year ended December 31, 2017, for shareholder review but does not include the data within this document.
Material Changes
No material financial changes or operational updates are detailed in this filing. The document focuses exclusively on corporate governance matters and the agenda for the upcoming shareholder meeting.
Guidance, Outlook, and Corporate Actions
The filing outlines several proposals for shareholder approval at the Annual General Meeting:
- Auditor Appointment: Appointment of Kesselman & Kesselman as auditors for 2018.
- Capital Increase: Approval to increase authorized share capital by 300 million Ordinary Shares.
- Board Re-election: Re-election of Ofer Tsimchi, Kenneth Reed, and Eric Swenden to the Board of Directors for three-year terms.
- Executive Compensation: Approval of a grant of 500,000 options to CEO Dror Ben-Asher and extensions of existing options for the CEO and Director Ofer Tsimchi.
- Plan Amendment: Approval of an amendment to the Amended and Restated Award Plan (2010).
Voting Requirements: Proposals regarding the CEO's options (Proposals 4 and 5) require a majority vote including a majority of non-controlling shareholders, or a limit on votes against by non-controlling shareholders not exceeding 2% of total voting rights.
Key Facts for Investor Verification
- Meeting Date: May 2, 2018, at 3:00 p.m. Israel time.
- Record Date: March 26, 2018.
- Capital Structure: Potential increase of 300 million Ordinary Shares pending approval.
- Executive Equity: New option grant of 500,000 shares to the CEO requires specific minority shareholder approval thresholds.
- Financial Data: Specific financial metrics for 2017 are not in this text; investors must refer to the full annual report or Form 20-F for detailed financials.